GeneDx Holdings Corp. — Director's Dealing 2025

Jul 31, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GeneDx Holdings Corp. (WGS)
CIK: 0001818331
Period of Report: 2025-07-29

Reporting Person: Stueland Katherine (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-07-29	Class A Common Stock	M	3874	—	Acquired	5594	Direct
2025-07-29	Class A Common Stock	S	2154	$105.31	Disposed	3440	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-07-29	Restricted Stock Unit	$	M	3874	Disposed		Class A Common Stock (3874)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3: Following the reported sales, in addition to the 3,440 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of
469,835 shares of Class A common stock and options to purchase up to an aggregate of 107,610 shares of Class A common stock, which RSUs and options vest according to their respective terms.

F4: 25% of the underlying shares each vest on April 29, 2023 and April 29, 2024, and 6.25% vest in quarterly installments thereafter until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.